Soyoung Park
Venture Capital | Innovation for Impact | Healthcare, Wellness, and Frontier | Duke MBA
San Francisco Bay Area
Invests in
Sectors:
Min Investment:
$100,000.00Max Investment:
$10,000,000.00Target Investment:
$500,000.00
Skills
Education
Lists including Soyoung
Work Experience
2024
General Partner
2024
At 1004 Venture Partners, we are dedicated to driving transformative innovations that enhance healthy aging and longevity. Our mission is to invest in groundbreaking technologies and visionary entrepreneurs who are redefining the future of health. By focusing on pre-seed, seed, and series A stage companies, we empower the next generation of pioneers in the longevity sector. Our strategic investments fuel the development of solutions that promote longer, healthier lives. Join us in shaping a future where aging is not just about living longer but living better.
2020
Investment Due Diligence Director
2023
Investment Due Diligence Manager
2020 - 2023
Analyst in Residence
2020 - 2020
HealthTech Capital is a group of private investors dedicated to funding and mentoring new "HealthTech" startups at the intersection of healthcare with digital technologies.
2023
Venture Partner
2023
VU Venture Partners is a multi-stage and multi-sector investment fund with offices in San Francisco and Hong Kong. VU's team is led by J. Skyler Fernandes, Andrew Zalasin, and James Zhang - top-performing investors with 45+ years of VC experience and a large number of successful investments such as Beyond Meat, Facebook, Uber, Twitter, Venmo, Oculus, Wish, Oscar, etc. We invest in Pre-seed through Series B rounds. Our initial investments range from $100K-$1M, and we will invest up to $10M in follow-on rounds. If you or anyone you know are raising capital for a startup, especially if it has enormous potential, please don't hesitate to reach out! #VC #VentureCapital #VUVenturePartners #VentureUniversity #VCTraining #Startups #Funding #Investments #PE #PrivateEquity
2022 - 2023
Clinical FP&A Senior Manager, R&D Finance, Rare Disease
2022 - 2023
Post-merger integration of the sickle cell disease equity Oxbryta and two late-stage drug development assets
2021 - 2023
Finance Lead, Clinical Development Finance Planning and Analysis Senior Manager
2021 - 2023
GBT is driven by a deep and urgent desire to improve the care of Sickle Cell Disease (SCD) patients. Beyond developing medicines, we are working to shine a bright light on the disparities and inequalities faced by people living with Sickle Cell Disease (SCD). Global Clinical Product Development Financial Planning & Analysis
2020 - 2020
Finance Project Consultant
2020 - 2020
Cost structure building for a new gene therapy pipeline
2018 - 2018
Corporate Controller Consultant, Associate Director of Accounting
2018 - 2018
2017 - 2017
Corporate Controller Consultant
2017 - 2017
2017 - 2017
Finance Project Consultant
2017 - 2017
2012 - 2016
Controller of Strategic Projects, Global Operations
2014 - 2016
Strategic global operation cost optimization projects for a $110M cost reduction
Controller of California, Global Operations
2012 - 2014
Post-acquisition Integration, new R&D pipeline commercialization, and SAP ERP system implementation